Skip to main content

Table 3 Efficacy of apatinib in patients with BTC

From: The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study

Parameter Total(n = 28)
n (%)
Monotherapy(n = 12)
n (%)
Combination therapy(n = 16)
n (%)
P
Best response     0.478
CR 0 (0) 0 (0) 0 (0)  
PR 6 (21.4) 2 (16.7) 4 (25.0)  
SD 15 (53.6) 8 (66.6) 7 (43.8)  
PD 7 (25.0) 2 (16.7) 5 (31.2)  
ORR 6 (21.4) 2 (16.7) 4 (25.0) 0.595
DCR 21 (75.0) 10 (83.3) 11 (68.8) 0.378
Median PFS (months) 4.3 4.2 4.9 0.867
Median OS (months) 6.2 7.0 6.1 0.871
  1. CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, ORR Overall response rate, DCR Disease control rate, PFS Progression free survival, OS Overall survival